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Abstract
More than 10 million people in the United States are known to have latent tuberculosis
infection (LTBI), and more than 300,000 begin treatment for LTBI annually. However,
many fail to adhere to therapy for numerous reasons. The purpose of this project was to
evaluate the impact of a new guideline, Targeted Tuberculin Testing and the Treatment of
Latent Tuberculosis, at an inner-city tuberculosis (TB) control clinic in the United States.
The practice-focused question for the project asked if the implementation of the clinical
guideline using a shorter regimen improved LTBI treatment adherence. The health beliefs
model was the framework used to guide the project. I analyzed data from deidentified
LTBI treatment adherence records of 12 patients before the change to the shorter
treatment regimens and 12 patient records 1 year after the change. Results after
implementation of the new treatment guideline showed no improvement in adherence.
Before the guideline implementation, 75% (n=9) of individuals had adhered to traditional
therapy whereas, after the shortened course was implemented, only 66.7% (n=8) of the
random sample adhered to treatment. It is important to evaluate new methods of
treatment and determine success early to promote health and reduce complications of
ineffective treatment of TB. These results can support positive social change by raising
awareness of the need to evaluate new treatment effectiveness early. Such knowledge can
help providers and clinicians examine the barriers to adherence to the medications used
for treating TB and implement appropriate measures to overcome the obstacles.
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Section 1: Nature of the Project
Introduction
Tuberculosis (TB) is a pandemic that is identified globally as the number one
cause of death worldwide (World Health Organization[WHO], 2015). In 2015, 10,000
individuals were diagnosed with TB in the United States. This figure represents a 1.6%
increase in the number of cases reported in 2014 (Centers for Disease Control and
Prevention [CDC], 2015). In 2014, 27 states reported an increase in TB. In 2015, 29
states including the District of Columbia reported further increases in TB cases; twothirds of the cases were from foreign-born patients. Furthermore, from 2011- 2015, the
TB case rate within this clinic in the northeastern United States decreased from
55/100,000 to 33/100,000. While this case rate in 2015 was 5.0 / 100,000 cases, it was
still above the national threshold of 2.0/100,000 (Department of Health HIV/AIDS,
Hepatitis, STD and TB Administration [DOHHAHSTA&TBA], 2016).
Tuberculosis (TB) and Latent Tuberculosis (LTBI) are Mycobacterium (MTB)
derived diseases. LTBI is the inactive form of MTB, and if treated it can prevent TB
infection by 70% to 90% (CDC, 2011). A diagnosis of TB occurs when someone who
living with LTBI develops symptoms such as fever, cough, and night sweats, etc. and
their sputum tests positive for Acid Fast Bacilli (AFB). Subsequently, the AFB’s
sensitivity reveals MTB (CDC, 2015;CDC Messages and Resources: U.S. Preventive
Services Task Force Recommendation on Latent Tuberculosis Infection, 2016).
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The HAHSTA annual report 2016 as well as the CDC and the WHO correlate the
decrease in the incidence and prevalence of TB with an increase active screenings and
rigorous adherence to treatment (CDC, 2015; WHO, 2016). A person with a LTBI
diagnosis has a MTB infection, but does not currently have active tuberculosis symptoms
(WHO, 2017). The symptoms of TB may include fever, night sweats, and a cough
lasting more than three weeks (CDC, 2015). It is estimated that 10 to 15 million
Americans have LTBI, but are asymptomatic and not infectious; however, they are at risk
of progression to active disease. Because of this risk, the treatment of LTBI is a critical
part of the elimination of TB (CDC, 2015).
More efforts are necessary to erradicate TB (CDC ,2014;WHO, 2017). Directly
observed therapy (DOT) is the administration of medication in the presence of medical
personnel. A combinationation of DOT, new and simpler treatment regimes, and efficient
diagnostic tools have been instrumental in decreasing the incidence and prevalence of TB
over the past 15 years (CDC 2015;WHO, 2015; WHO 2017). According to the Stop TB
Partnership, the goal to decrease the incidence of TB by 50% of 1990 figures is on track
in the Americas (WHO, 2017). Now that TB is on the decline, global health authorities
have declared that focusing on the treatment of LTBI is the single most effective way of
preventing TB (Munoz, 2015 LoBue, 2017; WHO, 2017).
Historically, LTBI is not a reportable disease (USPSTF,2016). New guidance
from the CDC suggests that local health departments can assist in TB elimination efforts
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by establishing a LTBI surveillance system, expand target testing in at-risk communities,
increase the use of shorter LTBI regimens, and partner with other agencies that care for
at-risk individuals (LoBue, 2017; WHO 2017). Consequently, the next phase in
eradicating this deadly contagion is prioritizing LTBI treatment in the global fight to
eliminate TB by the year 2050 (Cruz, Starke, and Lobato, 2014; Esmail, Barry, Young &
Wilkinson, 2014, WHO 2015; LoBue, 2017).
Despite the evidence demonstrating that LTBI treatment is necessary for TB
prevention (Horsburgh et al., 2010), the initiation and completion of LTBI treatment is
minimal (CDC, 2011). Fewer than half of LTBI patients in the United States who began
treatment completed the therapy (CDC, 2015). Researchers posit that the reasons for
nonadherence to LTBI interventions are varying. Grounds for nonadherence can range
from patient-centered issues such as medication reactions, economics, age, culture,
prolonged therapy, to facility or clinic centered issues, e.g. staffing (Ailinger, Martyn,
Laus & Lima, 2010; Horsburgh et.al, 2010; Li, Munsiff, Tarantino & Dorsinville, 2010).
The CDC published the clinical practice guideline, “Targeted Tuberculin Testing
and the Treatment of Latent Tuberculosis” in 2000 (Cohn, O'Brien, & Geiter,1999). This
hallmark guidance has been shown to improve LTBI medication adherence and improve
patient outcome (Holland, Sanders, Hamilton, & Stout, 2009). Authors assert the
guideine provides long-term cost saving; decreased incidence, prevalence, morbidity, and
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mortality related to TB; and improved overall community health (Holland, Sanders,
Hamilton, & Stout, 2009).
Background
During my tenure as an infectious disease nurse practitioner (NP) at an inner-city
health department clinic in the northeastern United States, the end of year surveillance
data revealed that the LTBI treatment adherence rate was 33%. In line with Holland et
al.’s (2009) observation that shorter regimes are less costly and can result in improved
LTBI treatment adherence, the clinic began offering two new regimens, one for 12
weeks, and another for four months. The new treatments were in addition to the standard
Isoniazid regimen of six and nine months respectively. The clinic administrators felt that
the change to shorter regimens would improve LTBI treatment adherence rates at the
clinic. While the current TB control guidelines do not require reporting of LTBI, this
clinic developed an in-house surveillance-tracking tool that allows for the monitoring of
patients who receive LTBI treatment.
The purpose of this project was to assess the impact of targeted
tuberculin testing and latent tuberculosis treatment at inner-city tuberculosis.
I assessed using the clinical guideline “target tuberculin testing and the
treatment of latent tuberculosis”, which is the global standard for assessment
and treatment of LTBI. The assessed period occurred at a (TB) control clinic
in the United States at two times: November 2011 and November 2012. I
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analyzed retrospectively, deidentified data of individuals who initiated
treatment of LTBI at the targeted clinic.
To conduct analysis, I obtained a letter of agreement that allowed me
to use the limited deidentified data. After obtaining the necessary signatures,
clinic staff randomly selected 12 records of individuals who initiated latent
tuberculosis treatment in November 2011 (2 months before the initiation of
the shorter LTBI regimens). Then clinic staff randomly selected 12 records of
individuals who initiated latent tuberculosis treatment in November 2012 (11
months after the initiation of the shorter regimens). Next clinic administrator
assessed each record for adherence, and she marked the patient as adherent if
the documentation in the client record reflected (no missed doses). Lastly, I
transferred the deidentified data to an excel spreadsheet and I analyzed it by
patient demographics including age, sex, country of origin, and LTBI
treatment regimens. My analysis was done to describe the characteristics of
the randomly selected population.
Demographic characteristics of the surveyed population were analyzed
using univariate analysis to denote if there were specific characteristics of
the population that adhered to LTBI treatment. I also described demographic
features of those who were nonadherent. I documented this information to
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foster an understanding of how such variables might influence LTBI
treatment adherence.
The implications for nursing practice include an opportunity to evaluate the
efficacy of the evidence-based practice guideline “target tuberculin testing and the
treatment of latent tuberculosis” in a clinical arena. It is also an opportunity to gather
data that may assist other clinicians who are working with the at-risk populations. Lastly,
I aimed to secure information that may help with improved and increased use of the
strategic practice guideline in other local clinics, doctors’ offices and hospitals.
There are several implications for social change aligned with national TB
reduction initiatives. In 2016 the United States Preventive Services Task Force (USPSTF)
and numerous other health organizations asserted that establishment of a reliable
surveillance system of LTBI would enable community stakeholders (i.e., patients,
medical providers, clinic staff, and surrounding community) to better manage and treat
at-risk individuals (LoBue, 2017). Relatedly, improved LTBI treatment adherence at this
clinic could decrease the incidence and prevalence of TB in the local community. Future
TB treatment healthcare costs related could be reduced. The project results can serve as a
tool to equip other practitioners with greater insight into understanding factors that may
affect LTBI treatment adherence. Consequently, there will be healthier community
outcomes. Ultimately, project results may contribute to improving overall management
of and care of at-risk individuals in this local community.
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In December 2011, the end of year cohort review surveillance data revealed that
the LTBI medication adherence rate at the clinic was 33% amongst primary contacts of
individuals infected with TB disease in 2011 (Anderson, 2011). During this meeting, the
staff discussed options to improve adherence. These discussions led a review of the
current literature on LTBI treatment. An article by Holland et al., (2009) documented
that shorter regimens were cost-effective and could improve adherence. As a result, the
clinic administrative staff decided to begin offering shorter regimens of Rifampin for four
months, and Rifapentine and INH for 12 weeks. The standard regimen of Isoniazid for
nine months (self- report) and six months via DOT continued as well. The evidencebased guideline “target tuberculin testing and the treatment of latent tuberculosis”, which
has been the global standard for the treatment of TB and LTBI since 1999, supported the
introduction of shorter treatment periods (Cohn, D. L., O'Brien, R. J., Geiter, 1999).
Problem Statement
The literature is replete with examples that LTBI treatment nonadherence is a
cause for concern (Esmail, 2014). While the research is robust with evidence that LTBI
treatment is effective (Butcher, 2013; (Lines, 2015), less than half of the individuals who
begin treatment of LTBI complete the required regimens (CDC, 2015; Salinas, 2016).
The inner-city TB control clinic where this project took place has a mission to "provide
tuberculosis (TB) prevention and control services to all residents, with the aim being to
decrease and eventual eliminate TB disease in the community (DOH, 2016; Tuberculosis
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and Chest Clinic, 2017). The clinic provides services to all people who live or work in the
community.
Purpose Statement
The purpose of this project was to examine LTBI treatment adherence at the
targeted clinic before and after the implementation of “targeted tuberculin testing and the
treatment of latent tuberculosis” infection guideline using the shorter LTBI treatment
regimens of Rifampin and Rifapentine with Isoniazid and compare it to the LTBI
treatment adherence before 2012. The practice-focused question for this project is “What
is the impact of LTBI treatment adherence after the implementation of the clinical
guideline ‘targeted tuberculin testing and the treatment of latent tuberculosis’ using
shorter regimens?” After obtaining a letter of agreement, the clinic administrator
collected the deidentified data relative to LTBI adherence from the records of patients
who were treated LTBI for one week in November 2011 and comparable data for one
week in November 2012. The two periods selected represent similar times; however,
November 2011 represents the period before the implementation of the shorter LTBI
treatment regimens. November 2012 represents the period 11 months after the
application of the newer regimens. The rationale for using these time periods was that I
was controlling for seasonal variations. The clinic staff member received an instruction
sheet along with the tool I designed to collect the data. The administrative staff member
accessed each file, recorded the medication regimen, adherence status, age, gender,
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country of origin on the data collection tool that I designed for this project. I analyzed the
deidentified data to assess patterns related to LTBI medication adherence and potentially
offer recommendations on how to improve the compliance rates of this population.
The Nature of the Doctoral Project
The project was a retrospective analysis of deidentified data provided by the clinic
administrative staff. The data included LTBI treatment adherence, demographic data, and
treatment information. This retrospective data provided a means for describing the
characteristics of a sampling of persons who accepted treatment of LTBI during
November 2011 and November 2012 respectively. The project also provided a list of the
regimens that were consistent with treatment adherence and nonadherence. The clinic
administrator marked the chart adherent if the evidence in the chart indicated no missed
doses or an endnote by the provider (physician or nurse practitioner) denoting treatment
adherence. I anticipated that the staff involved in patient care would be interested in the
project findings and wanted to participate in identifying ways to improve compliance and
completion.
Project Significance
The significance of this retrospective chart analysis is that information was
obtained that can give the clinic staff greater insight into identifying which demographics
or regimens may potentially be risk factors for nonadherence. It was also an opportunity
to get clinic specific data that could provide information to assist the clinic administrators
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in assessing which demographic characteristics may potentially be risk factors that may
impact LTBI treatment adherence. Lastly, it was an opportunity to evaluate the
effectiveness of the clinical guideline ‘targeted tuberculin testing and the treatment of
latent tuberculosis’ using the shorter regimens. The impact of this evidence-based
practice guideline using the shorter treatment regimens may assist this inner-city TB
control clinic with decreasing the community bacterial load of TB disease. Additionally,
this information will be shared with other community stakeholders which include
patients, clinic staff, other healthcare professionals within the community who care for atrisk populations, as well as the local and national government.
Summary
TB is a virulent infectious disease that has caused much devastation over the past
three decades (American Thoracic Society [ATS] and CDC, 2000). The treatment of
LTBI, which is the asymptomatic form of TB, has been shown to be the single most
effective way of combating the spread of TB (CDC, 2014). According to the CDC, more
than 300,000 individuals begin LTBI treatment but do not adhere to therapy for numerous
reasons which include medication side effects, prolonged regimens, economic factors,
and patient-provider related issues (Hirsch-Moverman,Da ftary,Franks, & Colson &
2008; Horsburgh, 2010; CDC, 2011). The purpose of this project was to the assess the
impact of ‘targeted tuberculin testing and the treatment of latent tuberculosis’ guideline
using shorter treatment regimens at inner-city tuberculosis (TB) control clinic in the
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United States at two times: November 2011 and November 2012. The significance of this
project is that it will allow healthcare practitioners and other key stakeholders to gain
insight into which demographic characteristics impact adherence. The project data
obtained may be helpful to the initiation of evidenced-based clinical guidelines. This
will allow nursing leadership to better manage individuals receiving LTBI medication,
assist with a tools to implement a surveillance system for LTBI, assist with the
refinement of evidenced-based regimens that improve patient outcomes, and ultimatey
improve LTBI treatment adherence at similar facilities in the future.
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Section 2: Background Context and Literature Review
Introduction
The LTBI medication adherence rate at the inner-city TB control clinic in the
northeastern. United States was 33% amongst primary contacts of individuals infected
with TB disease in 2011 (Anderson,Tuberculosis End of Year Surveillance, 2011). The
purpose of this capstone project was to assess the LTBI medication adherence rates at an
inner-city TB control clinic in the northeastern, United States. The practice-focused
question for this project is: “What was the impact of LTBI treatment adherence after the
implementation of targeted tuberculin testing and the treatment of latent tuberculosis
using shorter regimens?” To conduct the analysis, I first obtained a letter of agreement
that would allow me to use the limited deidentified data that collected by the clinic
administrator. After the contract was signed, permissions were granted, and the clinic
administrator randomly selected 12 records of individuals who initiated treatment of
LTBI November 2011 (2 months prior to initiation of the shorter regimens) and
November 2012 (11 months after the initiation of the shorter regimen). The rationale for
selecting these two periods is that November 2011 represents the 2 months before the
initiation of the shorter regimens and November 2012 represents the 11-month period
after the initiation of the shorter regimens). I chose these two times as a means of
controlling for seasonal variations. I analyzed and described the deidentified data by
denoting adherence status, as well as the characteristics of the populations who adhered
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or failed to adhere to the prescribed LTBI medication. I assessed the number of people
who successfully adhered to the treatment of Latent Tuberculosis LTBI at an inner-city
(TB) control clinic in the United States during the selected time frames of November
2011 and November 2012. The practice-focused question for this project is “What is the
impact of LTBI medication adherence after the implementation of targeted tuberculin
testing and the treatment of latent Tuberculosis using shorter regimens?” The next
section will cover the conceptual model, relevance to nursing practice, local background
and context, and a summary of the section.
Concepts, Models, and Theory
The health belief model (HBM) was initially developed in the 1950s by the
members of the United States Public Health Service to explain health behaviors related to
tuberculosis. The HBM is used to examine or explain health behaviors in many fields
and has been cited in thousands of studies since its inception (Rosenstock, 1974). The
major components of the HBM (which can be seen in the diagram in Appendix A) are:
1. Perceived susceptibility. Regarding LTBI medication adherence, an individual’s
perception of their susceptibility to acquiring ATB may be a precipitating factor
for adhering to therapy. Conversely, someone who does not adhere to therapy
may perceive or minimize their susceptibility of acquiring ATB.
2. Perceived severity. This concept describes the consequences of the condition,
behavior, or recommended actions; the consequence of not taking LTBI
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preventive therapy would be the potential of becoming infected with TB. The
recommended action is to take LTBI preventive therapy (Cohn et al., 2000).
Patients may not adhere to therapy if their perception of LTBI leads them to
believe they will be well without the therapy. Also, it is purported in the literature
that if LTBI patients feel that they “are not sick,” this could lead to either
nonadherence or failure to initiate TLTBI (ATS & and CDC, 2000).
3. Perceived benefits. This describes the desired actions and positive results for
acting. The benefits of taking LTBI preventive therapy are a 90 percent decrease
in the risk of acquiring Tuberculosis Disease (CDC, 2011). The nursing
implications with relevance to the HBM and our patient population include the
importance of adequately educating patients impacted by LTBI so that they may
comprehend the benefits of chemoprophylaxis and adherence to their regimens
(Zuniga, 2012).
4.

Perceived Barriers. The literature review contains ample information on client
and staff centered barriers to adherence. Strategies to improve TLTBI medication
adherence would include identifying the barriers and addressing them (Zuniga,
2012; Peluso et al., 2014).
5. Cues for Action. Several studies have cited nursing interventions as keys to
improving adherence.( Ailinger,2010) found that culturally competent Latino
nurse-management improved LTBI medication adherence.
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6.

Self-efficacy. Patients who successfully adhered to their prescribed regimens
have achieved self-efficacy as it relates to the Health Belief Model. Selfefficacy occurs when the person has completed treatment (Hodges & Videto,
2011). With relevance to this project; only 33% of individuals initiating
TLTBI achieved treatment adherence in 2011, therefore, self-efficacy
(Anderson, 2011).

The implications for nursing practice are these outcomes when disseminated, can
assist with the transmission of current knowledge and education which can foster
adherence. Understanding the health beliefs is essential to enhancing the patient's
knowledge base related to LTBI, its treatment options, medication side effects, and the
importance of adherence to TLTBI. Additionally, the literature has shown that
incentives, patient-provider relationship, economic factors, age, and directly observed
therapy (DOT) can improve adherence (Hirsch-Moverman, 2008; Horsburgh, 2010).
Summary of Theoretical Model
The health belief model is a theoretical framework that uses an individual’s health
beliefs as predictors of health prevention behaviors (Rosenstock, 1974). The six elements
of the HBM are central to understanding the environment surrounding an individual's
health choices. Regarding LTBI treatment adherence, it is essential to understanding
reasons why people chose to initiate treatment but fail to adhere to it. Future endeavors
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in this area will include inquiries into the individual's health beliefs in order ascertain if
the person's beliefs impacted health prevention behavior.
Relevance to Nursing Practice
The Institute of Medicine (IOM) has established that nurse leadership will be
essential in the implementation of programs that will allow for safe, adequate evidencebased care (IOM, 2010). The WHO has determined that the treatment of LTBI is the
single most effective way of preventing TB (WHO, 2013; CDC, 2012). The literature
shows that culturally competent nurse managers are facilitators of improved LTBI
medication adherence (Ailinger, 2010, Benjumea‐Bedoya, 2017). As a result, nurses
can be at the forefront of designing and implementing programs that assist with the
development of LTBI surveillance tools thereby helping with the elimination of active
TB disease by 2050 (Esmail, 2014; LoBue, 2017).
This formative evaluation of the clinical guideline "targeted tuberculin testing
[TTT], and the treatment of latent tuberculosis”, (Cohn 1999) will also highlight the
clinical outcomes relative to implementing shorter LTBI treatment regimens in this arena.
It is an opportunity to lead, change, and advance the current practices at this facility. The
success of obtaining guidance at this clinic will then result in the ability to share
information with other stakeholders, practitioners, and other facilities that care for at-risk
populations in the District of Columbia. Furthermore, this project is an opportunity to
initiate leadership in nursing practice in the arena of tuberculosis control. The DNP
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Exemplifies some of the “Essentials of the Doctor of Nursing Practice” (American
Association of Colleges of Nurses[AACN], 2006). These include several roles such as
researcher; understanding the scientific underpinnings of LTBI medication adherence;
Inter-professional collaborator; working with clinic staff, patients and other community
stakeholders while also functioning as an advanced practice nurse leader. Many
researchers established that “targeted tuberculin testing” using shorter regimens improves
LTBI medication adherence, improves patient outcomes, provides long-term cost saving,
decrease incidence, prevalence, morbidity, mortality related TB, and improves overall
community health (Holland et al., 2009; Horsburgh et al., 2010; Aspler, 2010).
Several studies have correlated nursing interventions with improved adherence
(Aspler et al., 2010; (M'Imunya, 2012; Zuniga, 2012). As a nurse leader, I intend to
disseminate the acquired data within the local community by educating healthcare
practitioners and patients on the benefits of treating LTBI. This information will be a
guide for assessing risk factors of individuals who may potentially be at risk for
nonadherence to LTBI preventive therapy.
Local Background and Context
Using the terms latent tuberculosis medication adherence and LTBI treatment
adherence, I conducted a review of the current literature utilizing several databases.
These databases included PubMed, and Google Scholar and Walden ProQuest. The
PubMed literature review search initially revealed 72 articles. I further refined the search
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to the last 5 years and later revealed 29 articles, of which 17 appeared to be relevant, to
this topic. There are some articles that I excluded due to their earlier publication date.
Furthermore, they did not directly relate to LTBI treatment adherence, or, they were
foreign in origin. A Google Scholar search resulted in more than 16,300 items in the
query. After further inquiry, 23 articles were relevant but were duplicates of the previous
such in Pub Med. The remainders of the articles were omitted due to irrelevance and
earlier dates. The search was later refined to view a “retrospective analysis of latent
tuberculosis medication adherence,” the years primarily tailored to 2010 – 2017 and
yielded an additional four articles. I used Some of the items with earlier dates due to
their historical content relative to LTBI treatment adherence.
Tuberculosis (TB) and Latent Tuberculosis Infection (LTBI). LTBI and are
diseases caused by (MTB) which is a bacterium that spreads from person to person
through the air (CDC, 2014). When a person with infectious TB coughs or sneezes,
droplets containing MTB float into the air. If another person inhales the droplets, he or
she is at risk of becoming sick with TB. However, not everyone infected with TB
becomes ill. Thus, two TB-related conditions exist: latent TB infection (LTBI) and TB
disease. Persons with LTBI are living with MTB but are not sick (CDC, 2014). The only
sign of LTBI is a positive reaction to either the tuberculin skin test or the interferon
gamma release assay (IGRA), which is a TB blood test. Persons with LTBI are not
infectious and cannot spread the TB infection to others (Munoz, Stagg & Abubakr, 2015).
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However, 10% of patients with LTBI will go on to develop active TB disease (CDC,
2014).
Global History and Incidence of TB and LTBI. The global health community
has targeted the year 2050 for the total elimination of TB (WHO, 2016). Over the last
two decades, rates of TB and LTBI have been drastically reduced due to several
internationally agreed upon targets by the WHO, United Nations (UN), and the CDC. By
2012, the incidence and prevalence of TB was decreased by 37%. There was also a 45%
reduction in mortality worldwide (Esmail et al., 2014; WHO,2017). However, despite
these efforts, TB remains active within specific countries, namely Brazil, Russia, India,
China, and South Africa. Moreover, an estimated one-third of the world's population has
LTBI (WHO, 2016). To bring global incidence of TB down, new approaches are
necessary (CDC, 2015). Research has demonstrated that one plausible solution to
addressing TB is to target and initiate the treatment of LTBI (Cohn et al., 2000; WHO,
2015).
TB Elimination in the United States. A review of the current literature reveals
that the treatment of latent tuberculosis infection (TLTBI) is crucial TB Elimination
(CDC, 2016). The Healthy People 2020 goal for LTBI treatment is that 79% of
individuals who initiate TLTBI should complete their treatment to achieve a decrease in
the case rate of TB disease in the United States (Office of Disease Prevention and Health
Promotion (ODPHP), 2016). Those at highest risk of converting from LTBI to TB
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disease are foreign-born or in close contacts of individuals with smear-positive TB
disease, children, immune-compromised individuals, people with diabetes, and
incarcerated individuals in any confined setting (Cohn et al., 2000; Cruz et al., 2014).
Worldwide, there were approximately 9.6 million cases of ATB in 2014 with
approximately1.5 million TB-related deaths (WHO, 2015). In the past quarter decade,
the incidence of TB in the United States was 3.0 cases/100,000. The TB case rate of
foreign-born individuals is 15.1/100,000, which is 13 times higher than the case rate for
people born in the United States, which is 1.2/100,000 (Salinas, Mindera & Hadad et al.
2016).
Tuberculosis Control. In the 1930s, this large metropolitan area in the United
States was one the tuberculosis ‘hot spots (Jones, 2015). This was attributed to its
prevalence in congested poor and neglected black communities. A period of 50 years of
effective treatment effectively brought TB under control until the mid-1980s and 1990s,
when there was an increase in the disease (Jones, 2015). The rate declined again during
the 2000s, but recent reports show that TB is on the rise for the first time in 23 years. is
one the regions reporting this increase in TB cases (Jones, 2015).
The mission of tuberculosis control is to provide tuberculosis (TB) prevention and
control services with the goal of the total elimination of TB in the community.
The DOH’s website for this inner-city clinic purports

21

“This clinic” is a specialty clinic and persons who have or are suspectected
of having tuberculosis are screened and evaluated there. Appointments
are not required at the clinic, but patients must have written referrals from
health care providers. The clinic does not perform routine TB screening,
such as those for job or school admission (Tuberculosis and Chest Clinic,
DOH,2017).
The clinic offers diagnostic medical management and LTBI and TB
treatment. The services at the clinic include skin testing for close contacts
to tuberculosis and high-risk individuals, chest x-rays, sputum collection,
medical management, including treatment, and case management and are
no cost to patrons.
Insurances are accepted to help defray the cost of services. Individuals receiving LTBI
services must come to the clinic by way of their own transportation.
This Northertheastern Mertropolitan city is surrounded by several other larger
metropolitian cities ond each side. (Hambrick, 2016).
The population of this Northeastern city was recorded as 658,893 in 2015. This
was an 8.9% increase from the 2010 figure of 604,912. The total number of TB cases in
2011 was 55/ case rate 8.9/100,000, in 2012 was 37/case rate 5.8/100,000 and 2013 was
37/5.9 per 100,000; total for this 3-year period is 130 cases of active TB disease
(Department of Health (HAHSTA), 2016). Statistical data on LTBI is not reportable

22

therefore it was not available in this report, but LTBI rates are tracked locally in the
clinic. Historically, since 2012 the clinic has averaged over 140 cases of LTBI annually.
In 2011, there were approximately 250 cases of LTBI and only 82/33% of individuals
who initiated LTBI treatment adhered to therapy (Anderson, End of Year Surveillance,
2011).
Patients come to the clinic via referral from several modalities. They may be
referred from other clinics, employment, corrections, parole, and probation or due to
Contact Investigation (contact to an individual with Active TB Disease). A nurse
practitioner or physician evaluates each client via a thorough history and physical exam.
If necessary, chest x-ray is obtained.

If the chest x-ray is normal with a positive

Mantoux skin test or IGRA blood test t-spot or Quantiferon TB gold test, patients are
offered LTBI therapy. Before initiation of LTBI therapy, baseline laboratory screening,
patient education on the medications and treatment course and the staff clinicians discuss
the risks and benefits of treatment. The patient is then given the option to accept or
decline treatment. This clinic uses patient pill count, self- report and in some instances
DOT as a means of measuring LTBI medication adherence.
Differentiating Latent Tuberculosis and TB Disease. A diagnosis of latent
tuberculosis infection is made based on an indurated Mantoux Skin Test (TST) usually
>10 mm, (5mm induration in immunocompromised individuals such as those with HIV);
or positive (IGRA), normal chest radiograph, history and physical exam and an
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asymptomatic state (CDC, 2014). In some instances, it may be necessary to obtain a
sputum sample to rule out TB disease. It is essential to ensure that TB disease is not
present to eliminate the inadequate risk treatment of TB, which can lead to a drugresistant strain of Tuberculosis. (CDC, 2014).
Targeted Tuberculin Testing and the Treatment of Latent Tuberculosis. In
1999, (ATS) published a clinical practice guideline that called for the screening of LTBI
in individuals who were high risk to reactivate or develop TB (American Thoracic
Society(ATS); CDC, 2000). Major risk factors for TB activation include HIV-infection.
Additionally, recent contact with an infectious TB patient, immigrants from a high TBburdened country, homelessness, inmates, people living in shelters, nursing homes,
people with diabetes, immunocompromised; including those people living with HIV and
young children (Horsburgh et al., 2010 (Cruz, 2014). The treatment of LTBI is the single
most effective means of preventing TB (WHO, 2015; CDC, 2014), thus, is a substantial
benefit for both the individual and the community when LTBI treatment is accepted, and
adherence is accomplished. The research reveals that an LBTI patient who has received
treatment has a 60% risk of developing active TB as compared to someone with LTBI
who is does not receive the treatment (WHO, 2017). Additionally, LTBI preventive
therapy can reduce the possibility of seroconversion to TB Disease for people who are
primary contacts (those in direct contact with TB infected patients) of individuals with
TB disease by 70 percent to 90 percent (Cohn, 2000; CDC, 2011)). However, about
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300,000 people begin LTBI treatment, but many do not adhere to the regimen (CDC,
2011). Horsburgh et al., (2010) demonstrated that the treatment of LTBI is necessary for
the prevention of TB, however acceptance, and completion of the LTBI treatment is
minimal. Fewer than half of the LTBI patients who began treatment completed the
therapy. Similarly, Smith and Menzies, (2011) found that approximately half of LTBI
patients studied completed the treatment.
Medication Adherence. Medication Adherence is the ability of an individual to
take medication as it is prescribed (WHO, 2003). The current literature on medication
adherence reveals that medication adherence in the general population is not sufficient
(Hirsh-Moverman et al., 2010; Horsburgh et al., 2010; Defulio & Silverman, 2012). In
2013, only 24 percent of Americans aged 40 or over living with chronic diseases adhered
to their prescribed course of therapy (National Community Pharmacist Association
(NCPA), 2013). Because of this discordance, medication nonadherence is a major cause
of morbidity and mortality in the world, costing the American healthcare system
approximately $290 billion annually. The national average for Latent Tuberculosis
Infection medication adherence ranged from 50 to 69 percent in 2008 (Horsburgh,
(2010). With the onset of newer regimens, DOT research has shown that these numbers
have significantly improved some adherence rates reaching 98% to 99% treatment
adherence and proven cost-effectiveness (Holland, 2009; Cruz, 2014).
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Factors Affecting Medication Adherence. Many factors can either enhance or
impede adherence (CDC, 2014; Zuniga, 2012). Some of the factors that hinder adherence
include adverse drug reaction, tardiness or missed appointments, and extended length of
therapy. Positive factors include sex, socioeconomic status, education, shorter
therapeutic regime, nationality, newly immigrated, strong provider-patient relationship,
and DOT(WHO, 2003; Hirsch-Moverman et al., 2008; Holland et al., 2009; Yeaw et al;
2009; Trajman et al., 2010; Horsburgh et al., 2010; Allinger et al., 2010; Blaschke, et al.,
2012; Glombliewski et al., 2012 NCPA, 2013; Peluso et al., 2014). Kwara (2008)
examined factors associated with LTBI medication adherence at a clinic in Rhode Island.
Results of this study show that of the 845 who were diagnosed with LTBI 645 (81.6%)
initiated TLTBI, 426 (61.7%) completed established therapy, 246 (35.6%) were lost to
follow-up, and treatment was discontinued in 18 clients (2.6%) Those clients who were
less adherent were noted to be younger <30; postpartum, uninsured, and reported side
effects.
Li et al., (2010) performed a retrospective analysis of LTBI medication adherence
rates at a New York City Health Department clinic for a two-year period including July
2002 to August 2004. The authors found that out of the 15, 035 individuals who
initiated treatment of Latent Tuberculosis Infection (TLTBI), there were 6788 (45.2%)
completers. Also, amongst those in this group who were more likely to complete therapy
were > 35 (52.5%), on Directly Observed Pharmacotherapy (DOPT) (71.4%), primary
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contacts (51.4 %), and taking the rifamycin based regimes which a "short course therapy"
60.0%). Those who were non-adherent 3758 (47.8%) were taking Isoniazid Therapy, and
59 (14.7%) were on the rifamycin based therapy. Lastly, a major factor that has impacted
LTBI medication adherence in the last five to ten years is the length of treatment.
Holland et al., (2009) found that “short-course therapy” of Rifampin for four months was
not only efficacious in yielding adherence rates as high as 82%; it was also more costeffective than the class "A" recommended medication Isoniazid for nine months.
Measurement of Adherence. Horsburgh et al., (2010) related that while the
treatment of Latent Tuberculosis is essential, the treatment of chronic and long-term
diseases could not be efficacious until patients adhere to their prescribed therapeutic
regimes. LTBI treatment is measured in several forms of direct or indirect observation.
Amongst the direct observation methods found in the literature were Directly Observed
Pharmaceutical Therapy (DOPT), drug level measurement, and clinic attendance. The
indirect methods of measuring adherence were patient self -report, pill count, electronic
monitoring devices (deemed more reliable), and prescription refill assessments (HirschMoverman et al., 2008 (CDC, 2015). LTBI treatment adherence rates (adherence being
measured by those who completed the prescribed therapy) in the United States and
Canada have historically been low, ranging from 35 to 64 percent for those initiating
Isoniazid regimen (Hirsch-Moverman et al., 2010, Rivest et al., 2013). LTBI adherence
rates for Rifampin based regimes have yielded higher completion rates with some studies
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reporting between 72 percent and 91percent for this four-month short-course therapy for
LTBI (Hirsch-Moverman et al., 2008; Holland et al., 2009). In conclusion, there are
many factors that can impact treatment adherence. The current evidence concludes that
compliance to treatment regimens improve with stronger provider -patient relationships,
shorter length of therapy, DOT, and cultural interventions amongst other ways (Holland,
2009; Ailinger, 2010;CDC,2011;Zuniga, 2012).
The Role of the DNP
While employed at the clinic (April 2011- September 2014), I was the nurse
practitioner who was responsible for evaluating the individuals who were screened for
LTBI. During the December 2011 cohort meeting, I was surprised to learn that so many
people failed to adhere to LTBI treatment. As a result, I began to review the literature on
LTBI medication adherence and found that poor adherence was not uncommon (HirschMoverman, 2008; Butcher, 2013). The role of the DNP in this project is multifaceted.
The DNP utilizes the Doctor of Nursing (American Association of Colleges of
Nurses[AACN], 2006)fill the leadership role in this project.
1. Role 1) DNP Essential I. She understands the "scientific underpinnings" that are
necessary to develop, assess, and evaluate individuals presenting for TLTBI.
2. Role 2) DNP Essential II. Organizational Leadership: She can lead; discerning
the need for change; in this case, improved adherence; researching trends related
to LTBI medication adherence, formulating a review and uses the data to educate
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the clinic staff, patients and other healthcare professionals who serve at-risk TB
communities.
3.

Role 3) DNP Essentials VI. She uses Inter-Professional Collaboration as a tool
in ensuring that patients diagnosed with LTBI have complete care. She provides
consults to lab, radiology to assess physical deficits. She communicates with the
TB control staff as necessary to determine to follow up on medication adherence.
At this clinic, there is an ongoing relationship between the physician and the
Advance Practice Nurse. This relationship allows continuous constant
communication to ensure that LTBI clients have the safest and accurate
evidenced-based care.

4. Role IV) DNP Essentials VII. & VIII. She is advanced practice nurse clinician
gathering information to assess a clinical prevention guideline. The literature has
shown that nursing interventions, the nurse-patient relationship, and nursemanaged projects positively affect LTBI medication adherence (Li, 2010;
Butcher, 2013; Benjumea‐Bedoya, 2017; AACN, 2006). The DNP functions as
the primary investigator for data analysis and compilation, education of staff, and
finally, complete the analysis needed to compile the outcomes. In the future, the
role of the DNP will be the leader in refining this gathered evidence to implement
the findings into practice, education other clinicians in the clinic as well as other
medical practices who care for at-risk populations about LTBI Medication
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treatment adherence. The impact of an evidence-based guideline such as
"Targeted Tuberculin Testing and the Treatment of Latent Tuberculosis (Cohn et
al., 1999)" utilizing regimens that are cost-effective, improve patient outcomes by
improving medication adherence, and decrease the incidence of TB in the local
community and the United States.
Summary
The current review of the literature reveals that targeted tuberculin testing and the
treatment of LTBI began in the late 1990’s. This serves as the guidance for TLTBI
(Cohn et al.,1999). Latent Tuberculosis treatment adherence rates have historically been
low ranging from 35 to 64 % on Isoniazid-based regimes (Hirsch-Moverman, 2008).
With the onset of newer "short course" therapy, LTBI medication adherence rates have
improved, and some studies show that adherence rates can be as high 72 to 91% (Holland
et al., 2009, Cruz, 2014). The Healthy People 2020 goal for LTBI medication adherence
is 79 % (ODPHD, 2016). LTBI treatment adherence is measured in various ways; either
directly or indirectly (Hirsch-Moverman et al., 2008; Horsburgh,2010); Sterling, 2011).
Adherence is accomplished when a patient either has taken the total number of prescribed
doses or completed the prescribed therapeutic regime (Hirsch-Moverman et al., 2008;
Horsburgh, 2010; Lines, 2015). The literature also reveals that there are positive and
negative factors associated with LTBI medication adherence. The negative factors can
include adverse drug reaction, tardiness, or missed appointments, and extended the length
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of therapy. The supportive factors include sex, socioeconomic status, education, shorter
therapeutic regime, nationality, newly immigrated, and strong provider-patient
relationship (Blaschke, 2012; Butcher, 2013; Hirsch-Moverman, 2008; Horsburgh, 2010;
Li, 2010).
Each year, more than 300,000 individuals begin LTBI treatment but do not
complete their regimens (CDC, 2011). Stringent surveillance of LTBI medication
adherence is crucial to the reduction of the incidence of ATB disease in the United States
and abroad (CDC, 2011; LoBue, 2017). Targeted Tuberculin Testing and the Treatment
of Latent Tuberculosis is the clinical guideline that established to assist with providing
evidence-based guidance for the treatment of LTBI (Cohn et al., 1999). In order to
improve treatment adherence, newer shorter regimens are available and have proven
efficacy with LTBI treatment adherence and cost-effectiveness (Holland et al., 2009;
(CDC, 2011; WHO, 2017). Walden University (2017) defines positive social change as
“a deliberate process of creating and applying ideas, strategies, and actions to promote
the worth, dignity, and development of individuals, communities, organizations,
institutions, cultures, and societies” (p.3). The implications for nursing practice and
social change include implementation of this evidenced-based guideline, which has
known efficacy and with appropriate application, and can lead to improved treatment
adherence and a reduction in the incidence, prevalence and eventual elimination of TB
locally and globally (CDC, 2015, WHO 2015). The analysis of these trends in adherence
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to LTBI medication can affect social change by assisting me in gaining insight into which
regimens improve adherence in this local community. This information can help in the
strategic implementation of services that can ultimately help the Department of Health
with improving TB elimination rates in this community. In 2011, there were 55/8.9%
/100,000cases of Active TB disease and approximately 295 cases of LTBI cases treated at
this clinic. Conversely, 2012 yielded 37/5.9%/100,000 cases of TB and 155 cases of
LTBI at this clinic (Department of Health (HAHSTA), 2016, (Anderson,Tuberculosis
Control 4th Quarter Cohort Meeting 2012)). This evidence shows that a reduction in the
incidence of TB in the world. Proper treatment will also decrease the impact of L.TBI in
the community. The latest guidance emphasizes the need for surveillance, an extension
of LTBI treatment outside of the local health department to other medical providers who
care for at-risk populations, and greater collaboration amongst the community
stakeholders. This includes the patients, medical providers at the clinic and in the
community and local and national government will ultimately assist this community with
attaining the target goal of 0.2 /100,000 TB case rate and eventually eradicate TB in the
community, the country, and in the end, the global community (LoBue, 2017). The role
of the DNP in the project is multifaceted. She exemplifies the “essentials of the doctor of
nursing practice” (American Association of Colleges of Nurses[AACN], 2006) as an
advanced practice nurse leader who understands the scientific underpinnings relative to
LTBI medication adherence. She utilizes the latest literature as guidance to exam the
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trends, and trouble-shoot problem areas. She partakes in Interprofessional collaboration
with stakeholders within the department of health and the community to formulate a
concrete system of surveillance of LTBI. This collaborative spirit can lead to a reduction
in TB disease within the local, national and international community. The next section
will cover data collection and analysis of evidence.

33

Section 3: Collection and Analysis of Evidence
Introduction
The LTBI treatment adherence rate at the inner-city TB control clinic was 33
percent amongst primary contacts of individuals infected with TB disease in 2011 (S.
Anderson, 2011). The purpose of this project was to examine LTBI treatment adherence
at the targeted clinic in the first week of November 2011, (which is two months prior
beginning the Target LTBI guideline using shorter regimes). This data was compared to
the first week of November 2012, (which is 11 months after the implementation of the
shorter regimens) to determine if improvement is seen in the LTBI adherence data. In
this project I analyzed deidentified data which was collected by the collect administrator
to assess a sampling of the number of people who successfully adhered to the treatment
of LTBI) at an inner-city TB clinic in the northeastern United States between in
November 2011 as compared to November 2012. The practice-focused question for this
project was “What was the impact of LTBI treatment adherence after the implementation
of targeted tuberculin testing and the treatment of latent tuberculosis using shorter
regimens?” at this inner-city clinic.
In this retrospective review of deidentified data, patient demographics, including
age, gender, country of origin, and LTBI treatment regimens were analyzed to assess if
there was improved LTBI treatment adherence in November 2012 as compared to a
sample taken from the previous year November 2011 when longer regimens Isoniazid
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based regimens were prescribed. The next section includes information regarding the
sources of evidence used in this project and the analysis and synthesis of the findings.
Sources of Evidence
The clinic administrator provided the necessary data for this retrospective
analysis. After obtaining a letter of agreement, clinic administrative staff randomly
selected 12 records from November 2011 and12 records from November 2012. I
provided an instruction sheet to the staff which explained the exact method for selecting
the charts. (see Appendix D). The sources of evidence were data from 12 patient charts
seen during the first week of November 2011 and the same number during November
2012. The rationale for using these time periods is to control for seasonal variance as
well as to document adherence before and after the implementation of shorter regimes.
The Clinic administrator extracted the deidentified data and placed it on the data
extraction tool I designed (See Appendix A). I wrote down specific instructions on how
written instructions to the clinic staff (see Appendix D). These records were the best
source of the information because the physician and nurse practitioners who provided the
care used these files to input all treatment-related documentation. The treatment regimens
are INH (Isoniazid); RIF (Rifampin) INH/RPT (INH and Rifapentine). If the client
adheren,ce was identified a mark would be placed in the adherence column. If the client
did not adhere, a mark would be placed in the nonadherence column. I analyzed
additional demographic, data (i.e., country of origin, gender, and age) to describe the
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characteristics of this population relative to adherence and nonadherence. The clinic
administrator marked the chart as adherence is assumed if documentation by the
physician or nurse practitioner denotes (no missed doses) or physician or nurse
practitioner treatment endnote denotes the individual took the medication as prescribed.
Analysis and Synthesis of Evidence
Data were abstracted from the charts by clinic administrative staff using a data
abstraction tool. After the staff collected the data, I entered the data into an Excel
spreadsheet. The number of the persons who adhered to LTBI treatment or were
nonadherent was documented on the worksheet. The descriptive statistics describe the
population, regimen and adherence status using total sum, and then further described in
terms of regimen, gender etc. percentages where applicable: The question for this project
was “What were the impact of targeted tuberculin testing and the treatment of latent
tuberculosis infection guideline using shorter regimens implemented in an inner-city TB
control clinic in January 2012?
Summary
This project was a retrospective cohort analysis, which assessed adherence rates
of individuals who accepted treatment for LTBI in an inner-city clinic. The practicefocused question for this project were: What were the impact of targeted tuberculin
testing and the treatment of latent tuberculosis infection clinical guideline using shorter
regimens implemented in an inner-city TB control clinic in January 2012? The sources
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of evidence gathered from the records located in the clinic. These files were the best
source information because the practitioners who carried out direct care directly input all
necessary information related to LTBI treatment within these documents. I analyzed the
deidentified data by comparing the adherence states of 12 patients before and after the
implementation of the clinical guideline targeted tuberculin testing and the treatment of
latent tuberculosis using shorter regimens. Analysis of demographic data includes a
description of the total number of people who adhered to each treatment regimen, gender,
age, and place of birth or country of origin. The clinic administrator randomly selected
charts and place the information on the data extraction tool that I designed for this
project. I obtained the deidentified data and placed it on an excel spreadsheet to analyze
the adherence and demographic information.
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Section 4: Findings and Recommendations
Introduction
The treatment of latent tuberculosis infection is the single most effective means
of decreasing the incidence of tuberculosis disease, which is the deadliest contagion of
our time (WHO, 2015). During my tenure at a TB, control clinic located in a large
metropolitan city the staff learned that the LTBI treatment adherence rate at the inner-city
TB control clinic was 33 % amongst primary contacts of individuals infected with TB
disease in 2011. In line with current treatment trends, which proved that shorter regimens
improved LTBI treatment adherence (Holland, Sanders, Hamilton, & Stout, 2009), the
administration decided to implement newer LTBI short-course regimens of Rifampin for
four months and INH and Rifapentine for 12 weeks. The old regimen of INH for nine
months was previously the most widely used.
The purpose of this project was to examine LTBI treatment adherence at the
targeted clinic before and after implementation of the LTBI guideline targeted tuberculin
testing and the treatment of latent tuberculosis. Two-time periods were chosen for the
evaluation. The first week was in November 2011, 2 months prior to beginning the target
LTBI guideline using shorter regime is. The second-time period was the first week of
November 2012, 11 months after the implementation of the shorter regimen. The goal of
the before and after the evaluation was to determine if improvement occurred in the LTBI
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adherence data after execution of the target LTBI guideline using the shorter regimes of
Rifampin for four months and INH and Rifapentine for 12 weeks (CDC Features: 2011).
(The old regimen was a nine-month course of INH.)
To determine adherence for the project, I assessed the number of people who
successfully adhered to the treatment of LTBI at an inner city (TB) control clinic in the
United States between November 2011 as compared to November 2012. The practicefocused question for the project was “What was the impact of LTBI treatment adherence
after the implementation of targeted tuberculin testing and the treatment of latent
tuberculosis using shorter regimens at this inner-city clinic?”
After receiving Walden IRB approval Number11-28-17-0328938, the clinic
administrator extracted the deidentified data from charts at an inner-city clinic for the
analysis. A random selection of 12 charts from November 2011 and November 2012 was
pulled, and the following information was extracted from each record; regimen,
adherence status, age, gender and country of origin. I analyzed and transcribed the
information recorded on the data extraction tool I developed for this project (see
Appendix B and C).
Findings
For November 2011, the data revealed that 66.7% (n=8) individuals treated with INH and
33.3% (n=4) individuals were treated with Rifampin (see Table 1). Of the 12 individuals
included in the sample 75% (n= 9) adhered to therapy, and 25% (n=3) did not adhere to
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therapy. When broken down by regimen, 75% (n= 6) of those who took INH adhered to
treatment and 75% (n=3) who adhered to INH also adhered to Rifampin therapy. There
were 25% (n=2) who took INH who did not adhere and 25% (n=1) of individuals who
did not adhere to Rifampin chemoprophylaxis. Demographics (see Table 2 and Table 3)
showed that 33% of individuals were from the United States, 16.7 %, from Ghana and
8.3% each were from six other countries that included Honduras, Nepal, Central African
Republic, Paraguay and Bangladesh. Fifty percent of participants were men and 50%
were women. The ages of this population ranged from 3 years to 68 years with ages of
the nonadherent individuals noted to be 43, 50 and women. In addition, a 3-year-old boy
who was nonadherent to therapy (attributed to parental nonadherence).
Table 1
November 2011 LTBI Adherence Data by Regimen
Regimen

Total Treated

Total
Nonadhered*

Number
Adhered*

INH
8
2
6
Rifampin
4
1
3
Total
12
3/25%
9/75%
Note: *Adhered= Took treatment as prescribed
*Nonadhered= did not take treatment as prescribed

Total
Percent
Adhered
75%
75%
75%
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Table 2
November 2011 Adherence by Country of Origin
Country of Origin
Number Treated
Total Adhered*
United States
4
3
Ghana
2
2
Bangladesh
1
1
Central Africa Rep
1
0
Ethiopia
1
1
Honduras
1
1
Nepal
1
1
Paraguay
1
0
Note: *Adhered = Took Medication as prescribed
*Nonadhered = did not take medication as prescribed

Total Nonadhered*
1
0
0
1
0
0
0
1

Table 3
November 2011 LTBI Adherence by Age and Gender of Population
Age
35
43
64
32
38
22
34
50
11
68
3
39

Gender
F
F
M
M
M
M
F
F
F
M
M
F

Adhered
x

Nonadhered
x

x
x
x
x
x
x
x
x
x
x
9(75%)

3(25%)

Findings for the November 2012 data revealed that 91.7% (n=11) were treated,
with INH therapy and 8.3% (n=1) was treated with Rifampin chemoprophylaxis. Of the

41

12 individuals included in the sample, 66.7% (n=8) adhered to therapy, and 33% (n=4)
did not adhere to therapy. When broken down by regimen, 63.6% adhered to INH and
36.4% did not adhere to INH. Only one person received Rifampin and that individual
was adherent to the therapy. As this was the year that the short course therapies of
Rifampin for four months and Rifapentine with INH for 12 weeks were supposed to be
prescribed, one question I asked was why patients were not prescribed these medications
in November 2012. Demographics of this population included 5the 0% (n= 6) the United
States and the other six individuals (1) each was from Guyana, Kenya, Morocco, Nigeria,
Philippines, and Salvador. The ages of individuals sampled ranged from 1 year to 84
years with nonadherence to INH therapy noted amongst one man aged 35 and onewoman age 43. There were also two children, ages 8 and 14, who did not adhere to
therapy; I attribute this to parental nonadherence.
A comparative analysis of the two groups of individuals reveals INH was the
primary prescribed treatment in both sampling years. In fact, in November 2012, when
short-course therapy of Rifampin for four months and Rifapentine with INH for 12 weeks
was supposed to be prescribed, INH was still widely prescribed because it was the most
used regimen at 91.7 % of the randomly selected charts. On the question of adherence,
75% adhered to their respective therapy in November 2011 and 66.7% adhered in
November 2012 (see Table 4). Therefore, it appears that while the total overall rate of
adherence was up in both years, individuals adhered less in 2012 compared to 2011.

42

Another look at the data reveals there were charts of three children in November 2012,
while there were two children in November 2011. In each group, parental nonadherence
was noted one case in the 2011 sample and in 2 cases in the 2012 sample.
Table 4
November 2012 LTBI Adherence Data by Regimen
Regimen

Total Treated

Total
Number
Nonadhered*
Adhered*
*INH
11
4
7
Rifampin
1
0
1
Total
12
4
8
Note: *Adhered = Took treatment as prescribed
*Nonadhered = did not take treatment as prescribed

Percent
Adhered*
63.6%
100%
66.7%

Table 5
November 2012 Adherence by Country of Origin
Country of
Origin
United States
Guyana
Kenya
Morocco
Nigeria
Philippines
Salvador

Number Treated
6
1
1
1
1
1
1
12

*Total Adhered/%

*Total Nonadhered/%

4
1
1
1
0
1
0
8/66.7%

2
0
0
0
1
0
1
4/33.3%

43

Table 6
November 2012 Adherence by Age and Gender
Age
16
1
14
39
8
43
59
35
84
62
45
45

Gender
F
F
M
M
M
F
F
M
F
M
M
M

Adhered
x
x

Nonadhered

x
x
x
x
x
x
x
x
x
x
8

Regimen
*INH
INH
INH
INH
INH
INH
INH
INH
INH
INH
INH
*RIF

4

Note: *INH = Isoniazid for nine months
*RIF = Rifampin for 4 months

Summary of Findings
In this project, I retrospectively examined a random sample of charts from
November 2011 and November 2012 to assess for adherence to a short regimen for latent
tuberculosis treatment. The premise of this project was to examine the impact on LTBI
treatment adherence after the implementation of short-course therapy of Rifampin for
four months. However, the data revealed that in the year of implementation, only one
individual in the project received the short course regime of Rifampin for four months.
The data did not support improved adherence in the year following implementation but
instead showed that there was continued use of Isoniazid therapy above the November
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2011 levels. These findings will be discussed at the dissemination meeting with clinic
personnel. Also, several potentially at-risk groups for nonadherence were identified. The
groups were women between the ages of 43 and 50, men in their 30s, and young children
who rely on their parents to ensure adherence.
Recommendations and Implications for Practice
There are several implications for practice which can be obtained from these
observations. 1) While the use of LTBI short-course therapy of Rifampin for four
months, Rifapentine with INH for 12 weeks has proven efficacious (Holland et al., 2009),
it did not appear in this small sample to be widely used during the year following
implementation of the short course therapy. Further investigation using a larger sample
for years succeeding the implementation phase of short-course therapy is recommended.
2) Three of the four nonadherent was a female and two children ages 8 and 14. The
clinic may need to target women and children for heightened adherence education.
Parental adherence education is needed to encourage parental participation in assisting
the children to adhere to the therapies. 3) It is imperative that findings of this project be
presented to the personnel in the clinic to explore these outcomes. As previously
discussed, there are numerous factors that impact adherence (Butcher, 2013;Esmail,
2014). The next section will discuss plans to disseminate the project findings, selfanalysis, and the project summary.
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Strengths and Limitations
This project involved a retrospective analysis of LTBI treatment adherence at a
clinic in a large metropolitan North Eastern City. The purpose of this project was to
examine LTBI treatment adherence at the targeted clinic before and after implementation
of the LTBI guideline targeted tuberculin testing and the treatment of latent tuberculosis.
The two-time frames selected were the first week of November 2011, which was 2
months before beginning the Target LTBI guideline using shorter regimes and the first
week of November 2012, which was 11 months after the implementation of the shorter
regimen. The goal of the before and after the evaluation was to determine if improvement
occurred in the LTBI adherence data after implementation of the Target LTBI guideline
using the shorter regimes of Rifampin for four months and INH and Rifapentine for 12
weeks.
Two of the weaknesses of this project include small sample the size and the
limited amount of data to evaluate the short course therapy. The same that I was supplied
did not support this evaluation because only one individual was prescribed the short
course treatment in the year following the implementation of the therapy. Conversely,
there was continued use of the Isoniazid therapy. Two of the strengths of this project are
that while short course therapy was not adequately evaluated, LTBI treatment adherence
was, evaluated and there were several identifiable issues noted: 1) INH continued to be
widely used in this population despite the decision of administrative and clinical staff to
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use short-course therapy.2) While nonadherence was identified amongst men, women,
and children of grave concern was the phenomenon of parental nonadherence which puts
young children at risk for treatment failure. This identifies a need to ensure adequate
programs for parental adherence education.
The findings this project, when disseminated back to the clinic, may be used as
guidance to improve clinical and administrative services to these at-risk populations.
Summary
In this project, I analyzed LTBI treatment adherence retrospective data from an
inner-city clinic in the United States. While the goal was to analyze the implementation
of short course Rifampin and Rifapentine with INH treatment the collected data only
contained one sample of an individual who was prescribed Rifampin for 4 mos. Future
projects in this area should include a larger sample and evaluations should be done in
years beyond the initial implementation.
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Section: 5 Dissemination Plan
In this project, I retrospectively examined a sampling of individuals who accepted
treatment for LTBI at an inner-city clinic in the United States. Each quarter, the clinic
holds a quarterly case management meeting. I will request a forum during this time to
discuss the finding of the project. In addition, at year’s end there is an annual cohort
analysis which includes members of the at-large community, clinic staff, correctional
medicine personnel, volunteer community members, and other nurses and clinicians from
local practices. I will also request a forum during this event to disseminate this
information and its implications to other concerned parties.
Analysis of Self
In my role as a family nurse practitioner, I have always had a sense of obligation
to provide the best, evidence-based care to my constituents. It was in my capacity as
nurse practitioner at this inner-city clinic that I realized that there were many people who
would accept treatment for LTBI but failed to adhere to therapy. As I became more
involved in the clinic and began attending conferences at the National Tuberculosis
Controllers meetings, I realized that this phenomenon was not isolated to our clinic, but it
was a national epidemic. As I listened to the presenters discuss the problems and
solutions to this issue in their local communities, I was motivated to troubleshoot the
problem in my own local community clinic. Some of the questions I asked myself were:
What is impacting out patient’s ability to adhere to the therapy? How can we make it
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easier for them to adhere to therapy? Are there barriers within our clinic composition,
staffing etc. that impedes patient adherence? This project was birthed out of my desire to
explore ways to improve adherence to LTBI therapy because the literature showed that it
is the number one way to decrease the incidence of tuberculosis disease locally,
nationally and internationally (WHO, 2015).
The "Essentials of the Doctor of Nursing Practice" are part of me. Not only have
I developed an understanding of the scientific underpinnings of research, but I also
understand that my role as an advanced practice nurse entails the use of interprofessional
collaboration to promote the health of the local and global community. These tools of
nursing are the keys to healing this world. In addition, in my capacity as the founder of
an international health outreach organization, God’s House International, I can ignite
social change and social justice which allows individuals who may not have an
opportunity to receive quality healthcare to enjoy the same equalities of evidenced-base
care in the countries that we serve. In the article published by the Institutes of Medicine,
“Nurses Leading Change: Advancing Health” (IOM, 2010) nurses are targeted as the
professionals who have changed and will continue to lead the way healthcare is delivered
in these United States and abroad. Because of this project, I plan to continue to ignite
change and examine other options in my current and future work arenas to implement
evidence-based quality care to the populations that are in my community.
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Summary
Tuberculosis disease is global contagion infecting 10.4 million individuals in
2016 (Geneva: WHO; 2017). The treatment of LTBI is the single most effective way to
prevent TB disease. In this project, I retrospectively analyzed LTBI treatment adherence
at an inner-city clinic in the United States. I implemented this endeavor to examine
adherence status of individuals who accepted treatment of LTBI at two-time frames;
November 2011 and November 2012; the latter being 11 months after the implementation
of targeted tuberculin testing and the treatment of latent tuberculosis infection using
shorter regimes. The clinic administrator collected the data and the deidentified data,
along with other patient demographics, placed on a data extraction tool by the personnel.
Afterward, the collected data was given to me, and I then placed it on an excel
spreadsheet for analysis. While the findings did not support improved adherence after the
implementation of the shorter course therapy, there were some findings and
recommendations that should be noted. 1) Within the sampled population there was poor
adherence amongst children and women between the ages of 43 and 50. 2)
Recommendation for improved parental adherence education and heightened adherence
education amongst middle-aged women. 3) Recommendations for reexamination of this
study using a larger sample. 4) Recommendation that information is disseminated to the
clinic and at-large community.
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The treatment of LTBI is crucial in the fight to end TB disease. The WHO, CDC
and the Pan American Health Organization have collaborated with high and low
incidence countries in efforts to decrease the incidence and prevalence of TB worldwide.
At the local level, in the United States, it is imperative that partnerships are created with
other clinicians, facilities and organization to assist in these efforts. Adherence
education for the young, the old, foreign-born, and native-born Americans is a one of the
keys to improving adherence amongst at-risk populations. We must “leave no one
behind” in our efforts to end TB. There can be no “community” without the word
“unity”
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Appendix A:Health Belief Model

Individual’s Health Perceptions
Am I sick?

Perceived Susceptibility

Perceived Benefits

Plus

Minus

Perceived Severity

Perceived Barriers

(Likelihood of individual to practice)

Cues to action:
Health Prevention Behavior
1. Phone call reminders
2. Provider /patient
relationship
3. Finances
4. Age
5. Socioeconomic status
6. Cultural beliefs
7. Incentives
8. Phone call reminders
9. PR /patient
relationship
10. Finances
11. Age
12. Socioeconomic status
13. Cultural beliefs
14. incentives

Self-Efficacy
LTBI Treatment Adherence
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Appendix B November 2011 Data Collection Tool

Chart Regimen

Adh NAdh Age Sex COA

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

Ad Adherence

N/Adh—Nonadherence-

COA—Country of Origin
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Appendix C: Data Collection Tool (November 20

Chart Regimen

Adh NAdh Age Sex COA

13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.

Ad Adherent

N/Adh—Non-

COA Country of Origin
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Appendix D: Instructions for Data Collection
1. Select 12 charts, choosing every third chart, for patients seen during the month of
November 2011 and November 2012 Respectively. DO NOT DUPLICATE.
2. For each chart document on the Data Collection Tool these findings
a. LTBI treatment regimen e.g., INH/ Rifampin/Rifapentine/INH
b. Adherence status (took medication as prescribed?
c. Non- Adherence did not take medication as prescribed) (had missed doses)
d. Sex: Male /Female/Transgender
e. Date of Birth
f. Country of Origin
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Appendix E
Summary of Targeted Tuberculin Testing and the Treatment of Latent Tuberculosis
1. Specific high-risks populations are “targeted” for TB testing:
a. Foreign born
i. Primary contacts of people infected with TB
ii. New Immigrants
b. immunocompromised
i. HIV
ii. Diabetic
iii. Transplant
c. incarcerated or individuals in group facilities
i. nursing homes
ii. half-way houses
iii. drug treatment programs
2. Test these individuals
3. Treat to prevent active TB disease

